GASTROINTESTINAL STROMAL TUMORS
Clinical trials for GASTROINTESTINAL STROMAL TUMORS explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMORS trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat stomach tumors
Disease control OngoingThis early-stage study is testing the safety and effectiveness of a new drug, TAS-116, when given alongside the standard drug imatinib. It is for people with advanced gastrointestinal stromal tumors (GIST) whose cancer has continued to grow despite taking imatinib. The goal is to…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for patients whose stomach cancer stopped responding to standard drug
Disease control OngoingThis study is testing whether adding a new drug called bezuclastinib to an existing cancer drug (sunitinib) can help control advanced gastrointestinal stromal tumors (GIST) that have started growing again on sunitinib alone. It will involve about 40 adult patients who have a spec…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: Sarcoma Alliance for Research through Collaboration • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for tough stomach tumors: Head-to-Head drug battle
Disease control OngoingThis study compares two drugs, ripretinib and sunitinib, for patients with advanced gastrointestinal stromal tumors (GIST) whose cancer has worsened or who couldn't tolerate the standard first treatment, imatinib. About 453 patients worldwide will take one of the two drugs daily …
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 17, 2026 13:10 UTC
-
Targeted drug tested for Tough-to-Treat stomach tumors
Disease control OngoingThis study is testing whether the drug regorafenib can help control rare, hard-to-treat types of gastrointestinal stromal tumors (GIST) that have specific genetic mutations. It is for adults whose cancer has continued to grow despite standard first-line treatment. The main goal i…
Matched conditions: GASTROINTESTINAL STROMAL TUMORS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC